J Larkin
Overview
Explore the profile of J Larkin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
4049
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sugiyama K, Gordon A, Popat S, Okines A, Larkin J, Chau I
ESMO Open
. 2025 Jan;
10(2):104122.
PMID: 39874902
Pathological response (PR) is an oncological outcome measure that indicates the therapeutic response to neoadjuvant therapy. In clinical trials involving neoadjuvant or perioperative interventions, overall survival and disease/event-free survival are...
2.
Choueiri T, Penkov K, Uemura H, Campbell M, Pal S, Kollmannsberger C, et al.
Ann Oncol
. 2024 Dec;
PMID: 39706335
Background: In the phase III JAVELIN Renal 101 trial (NCT02684006), first-line treatment with avelumab + axitinib resulted in significantly longer progression-free survival (PFS) and a higher objective response rate (ORR)...
3.
Robert C, Long G, Larkin J, Wolchok J, Hassel J, Schadendorf D, et al.
Eur J Cancer
. 2024 Nov;
214:115119.
PMID: 39612757
Purpose: To investigate the predictive value of RECIST response within 3, 6, or 12 months on long-term survival, and explore differences between nivolumab+ipilimumab and nivolumab monotherapy, we analyzed pooled 5-year...
4.
Long G, Carlino M, McNeil C, Ribas A, Gaudy-Marqueste C, Schachter J, et al.
Ann Oncol
. 2024 Sep;
35(12):1191-1199.
PMID: 39306585
Background: Pembrolizumab significantly improved overall survival (OS) versus ipilimumab for unresectable advanced melanoma in KEYNOTE-006 (NCT01866319); 10-year follow-up data are presented. Patients And Methods: Patients with unresectable stage III or...
5.
Abratenko P, Aduszkiewicz A, Akbar F, Pons M, Asaadi J, Aslin M, et al.
Eur Phys J C Part Fields
. 2023 Jun;
83(6):467.
PMID: 37303462
The ICARUS collaboration employed the 760-ton T600 detector in a successful 3-year physics run at the underground LNGS laboratory, performing a sensitive search for LSND-like anomalous appearance in the CERN...
6.
Haanen J, Larkin J, Choueiri T, Albiges L, Rini B, Atkins M, et al.
ESMO Open
. 2023 Apr;
8(3):101210.
PMID: 37104931
Background: We report updated data for avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma from the third interim analysis of the phase III JAVELIN Renal 101...
7.
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al.
Ann Oncol
. 2022 Oct;
33(12):1217-1238.
PMID: 36270461
No abstract available.
8.
Tomita Y, Larkin J, Venugopal B, Haanen J, Kanayama H, Eto M, et al.
ESMO Open
. 2022 Aug;
7(5):100564.
PMID: 36037566
Background: C-reactive protein (CRP) is an important prognostic and predictive factor in advanced renal cell carcinoma (aRCC). We report the association of CRP levels at baseline and early after treatment...
9.
Abed Abud A, Abi B, Acciarri R, Acero M, Adames M, Adamov G, et al.
Eur Phys J C Part Fields
. 2022 Jul;
82(7):618.
PMID: 35859696
DUNE is a dual-site experiment for long-baseline neutrino oscillation studies, neutrino astrophysics and nucleon decay searches. ProtoDUNE Dual Phase (DP) is a 6 6 6 m liquid argon time-projection-chamber (LArTPC)...
10.
Ferguson L, Ho B, Weir J, Francis N, West K, Rathbone B, et al.
Skin Health Dis
. 2022 Jun;
1(1):e8.
PMID: 35664814
We report a 73-year-old female with metastatic renal cell carcinoma who developed a widespread lichenoid reaction following nivolumab treatment. The timeline of the reaction strongly correlated with the nivolumab treatment...